Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ImClone (IMCL), Bristol-Myers (BMY) and Merck KGaA (FSE:MRK) agreed to co-develop and co-commercialize Erbitux
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury